Free Trial
NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

CureVac logo
$5.41 +0.02 (+0.37%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.40 -0.02 (-0.28%)
As of 08/1/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CureVac Stock (NASDAQ:CVAC)

Key Stats

Today's Range
$5.36
$5.42
50-Day Range
$4.07
$5.60
52-Week Range
$2.37
$5.72
Volume
516,327 shs
Average Volume
838,251 shs
Market Capitalization
$1.21 billion
P/E Ratio
5.88
Dividend Yield
N/A
Price Target
$6.83
Consensus Rating
Hold

Company Overview

CureVac Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

CVAC MarketRank™: 

CureVac scored higher than 72% of companies evaluated by MarketBeat, and ranked 262nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CureVac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CureVac has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CureVac's stock forecast and price target.
  • Earnings Growth

    Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CureVac is 5.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CureVac is 5.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

  • Price to Book Value per Share Ratio

    CureVac has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CureVac's valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CureVac does not currently pay a dividend.

  • Dividend Growth

    CureVac does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.11% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, CureVac insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 2.15% of the stock of CureVac is held by insiders.

    • Percentage Held by Institutions

      Only 17.26% of the stock of CureVac is held by institutions.

    • Read more about CureVac's insider trading history.
    Receive CVAC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

    CVAC Stock News Headlines

    UBS Downgrades CureVac N.V. (CVAC)
    Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift
    Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.
    See More Headlines

    CVAC Stock Analysis - Frequently Asked Questions

    CureVac's stock was trading at $3.41 at the beginning of the year. Since then, CVAC shares have increased by 58.7% and is now trading at $5.41.

    CureVac N.V. (NASDAQ:CVAC) issued its earnings results on Thursday, May, 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.08. The company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a trailing twelve-month return on equity of 30.89% and a net margin of 35.44%.

    CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

    Top institutional investors of CureVac include Ballentine Partners LLC (0.02%), Signaturefd LLC (0.01%), Baron Wealth Management LLC (0.01%) and Green Alpha Advisors LLC (0.01%).

    Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

    Company Calendar

    Last Earnings
    5/22/2025
    Today
    8/02/2025
    Next Earnings (Estimated)
    8/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CVAC
    CIK
    1809122
    Employees
    880
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $10.00
    Low Price Target
    $5.00
    Potential Upside/Downside
    +26.3%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.20
    Research Coverage
    5 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    $0.92
    Trailing P/E Ratio
    5.88
    Forward P/E Ratio
    7.51
    P/E Growth
    N/A
    Net Income
    $175.50 million
    Net Margins
    35.44%
    Pretax Margin
    39.67%
    Return on Equity
    30.89%
    Return on Assets
    25.54%

    Debt

    Debt-to-Equity Ratio
    0.05
    Current Ratio
    7.65
    Quick Ratio
    7.64

    Sales & Book Value

    Annual Sales
    $579.18 million
    Price / Sales
    2.10
    Cash Flow
    $0.88 per share
    Price / Cash Flow
    6.17
    Book Value
    $3.36 per share
    Price / Book
    1.61

    Miscellaneous

    Outstanding Shares
    224,340,000
    Free Float
    219,515,000
    Market Cap
    $1.21 billion
    Optionable
    Optionable
    Beta
    2.53

    Social Links

     The Best Nuclear Energy Stocks to Buy Cover

    Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

    Get This Free Report

    This page (NASDAQ:CVAC) was last updated on 8/2/2025 by MarketBeat.com Staff
    From Our Partners